LY 3045697Alternative Names: LY-3045697
Latest Information Update: 02 Oct 2015
At a glance
- Originator Eli Lilly
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 01 Sep 2013 Eli Lilly completes a phase I trial in Healthy volunteers in the Netherlands (NCT01821703)
- 25 Jul 2013 Eli Lilly completes a phase I volunteer trial in Netherlands (NCT01750853)
- 09 Jul 2013 Eli Lilly initiates enrolment in a phase I trial in Cardiovascular disorders (healthy volunteers) in Netherlands (NCT01821703)